BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
View original at globenewswire.comBioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cance…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
BNT326/YL202 showed antitumor activity and favorable safety profile in advanced or metastatic NSCLC patients who progressed after standard of care therapy
60% confidenceGotistobart showed a 54% reduction in the risk of death compared with standard of care chemotherapy in squamous NSCLC patients who progressed on prior immunotherapy plus chemotherapy
60% confidencePumitamig plus chemotherapy showed encouraging preliminary antitumor activity and survival outcomes with manageable tolerability profile as first-line therapy in extensive-stage small cell lung cancer
60% confidenceBioNTech aims to offer patients with lung cancer transformative treatment options that help provide meaningful long-term benefit across all stages of the disease
60% confidenceBioNTech continues to advance differentiated treatment approaches across lung cancer settings while building clinical evidence to guide further development
60% confidenceThe data presented at ELCC 2026 further define the potential of BioNTech's late-stage portfolio in lung cancer
60% confidence
Data points we hold from this source
| BioNTech SE · ongoing phase3 trials | 4 trials |
| BioNTech SE · ongoing clinical trials | 16 trials |
| BioNTech SE · ongoing novel novel combination trials | 5 trials |